Science News: Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care
April 12, 2021
Chronic inflammatory demyelinating polyneuropathy (CIDP) is without a disease activity biomarker and has broad clinical heterogeneity. This review article summarizes clinical and diagnostic tools which can be used in clinical practice to help the clinician to just the outcome of the patient and determine if the treatment is effective or not.
Patient Safety: EMG/NCS and Risk of Bleeding
March 30, 2021
Electrodiagnostic testing (needle electromyography) in patients with bleeding diathesis is associated with greater risk of bleeding when compared to general population. It is recommended that caution should be used when deciding on electrodiagnostic testing in patients with platelet counts less than 50,000 and INR greater than 1.5-2.0.
Science News: Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
March 29, 2021
This was a retrospective cohort study conducted in a university hospital in Sweden to compare efficacy between rituximab and conventional immunosuppressants in the refractory and newly diagnosed generalized myasthenia gravis.
Sandra Hearn, MD, Receives 2021 Surinderjit Singh Young Lectureship Award
March 21, 2021
The AANEM is excited to announce that Sandra Hearn, MD, is the 2021 winner of the Surinderjit Singh Young Lectureship Award. Dr. Hearn was chosen by AANEM President Bonnie Weigert, MD. As part of the award, Dr. Hearn will be a plenary speaker at the 2021 AANEM Annual Meeting in Aurora, Colorado, which will take place October 13-16. Her plenary is called, “Pushing the Boundary of Normal in Electrodiagnostic Interpretation.”
Science News: Which Ultrasound Parameter is More Accurate in the Diagnosis of Carpal Tunnel Syndrome
March 17, 2021
Ultrasound (US) can be useful to diagnosing carpal tunnel syndrome (CTS). Most US CTS studies have looked at median nerve cross sectional area (CSA). Others use resistive index (RI) or strain ratio (SR) as the criteria. This study compared CSA with RI and SR in CTS.
Science News: Serum Neurofilament Light Chain Predicts Long-Term Prognosis in Guillain-Barré Syndrome Patients
February 16, 2021
The neurofilament light (NfL) chain is an increasingly studied biomarker for axonal injury, previously studied in Guillain-Barré syndrome (GBS). This study evaluates it as a prognostic maker in GBS.
Science News: Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series
February 02, 2021
Eculizumab has been approved and used for AChR antibody positive myasthenia gravis but little is known about its efficacy for AChR seronegative cases. In this small retrospective study (N=6), treatment outcome with eculizumab for AChR negative patients was assessed.
President Biden’s Initial Health Care Priorities
January 25, 2021
On Wednesday, January 20, President Joe Biden was sworn in as the 46th President of the United States. In typical presidential fashion, shortly after being sworn in, President Biden issued several executive orders, many of which related directly to health care and, more specifically, the COVID-19 pandemic. Furthermore, as is customary, members of President Trump’s administration, including the heads of HHS and CMS, resigned their positions prior to Biden’s swearing-in.
Science News: Placebo Effect in Chronic Inflammatory Demyelinating Polyneuropathy: The PATH Study and a Systematic Review
January 19, 2021
Placebos (pharmacologically inert preparations) are used in treatment trials to assess the true effect of trial medication. Placebo responses have been noted in chronic inflammatory demyelinating polyneuropathy (CIDP) trials including the most recent PATH trial investigating subcutaneous IVIG as maintenance therapy.
COVID-19 Vaccine: AANEM Publishes Guidance for Patients with NMDs
January 14, 2021
At the end of 2020, with announcement of the impending approval of not one but two vaccines against COVID-19, AANEM staff faced a sudden influx of phone calls and emails from members, nonmember physicians, and even some NM patients inquiring about the safety of such vaccines for NM patients. The AANEM Quality & Patient Safety Committee quickly took up the task of researching the data available on the COVID-19 vaccines, as well as looking at the safety and efficacy of vaccines in general in this patient population.